A detailed history of Advisor Group Holdings, Inc. transactions in Harmony Biosciences Holdings, Inc. stock. As of the latest transaction made, Advisor Group Holdings, Inc. holds 907 shares of HRMY stock, worth $31,908. This represents 0.0% of its overall portfolio holdings.

Number of Shares
907
Previous 235 285.96%
Holding current value
$31,908
Previous $7,000 414.29%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

BUY
$30.0 - $39.95 $20,160 - $26,846
672 Added 285.96%
907 $36,000
Q2 2024

Aug 13, 2024

BUY
$28.81 - $33.01 $6,770 - $7,757
235 New
235 $7,000
Q4 2023

Feb 12, 2024

SELL
$19.2 - $33.78 $51,513 - $90,631
-2,683 Reduced 84.5%
492 $15,000
Q3 2023

Nov 13, 2023

BUY
$31.89 - $39.03 $46,304 - $56,671
1,452 Added 84.27%
3,175 $104,000
Q2 2023

Aug 10, 2023

SELL
$30.5 - $37.4 $18,940 - $23,225
-621 Reduced 26.49%
1,723 $60,000
Q1 2023

May 12, 2023

SELL
$30.8 - $53.92 $279,386 - $489,108
-9,071 Reduced 79.47%
2,344 $76,000
Q4 2022

Feb 10, 2023

BUY
$45.4 - $60.91 $293,193 - $393,356
6,458 Added 130.28%
11,415 $628,000
Q3 2022

Nov 14, 2022

SELL
$42.06 - $55.45 $552,584 - $728,502
-13,138 Reduced 72.61%
4,957 $219,000
Q2 2022

Aug 10, 2022

SELL
$33.54 - $52.15 $52,557 - $81,719
-1,567 Reduced 7.97%
18,095 $882,000
Q1 2022

May 04, 2022

BUY
$33.14 - $51.13 $647,091 - $998,364
19,526 Added 14357.35%
19,662 $957,000
Q3 2021

Nov 05, 2021

BUY
$25.68 - $38.61 $3,492 - $5,250
136 New
136 $5,000
Q1 2021

May 13, 2021

SELL
$27.56 - $40.37 $6,890 - $10,092
-250 Closed
0 $0
Q3 2020

Nov 12, 2020

BUY
$30.96 - $44.39 $7,740 - $11,097
250 New
250 $8,000

Others Institutions Holding HRMY

About Harmony Biosciences Holdings, Inc.


  • Ticker HRMY
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 59,161,400
  • Market Cap $2.08B
  • Description
  • Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, develops and commercializes therapies for patients with rare neurological disorders in the United States. Its product, WAKIX is a medication for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. The company was formerly known as Harmony ...
More about HRMY
Track This Portfolio

Track Advisor Group Holdings, Inc. Portfolio

Follow Advisor Group Holdings, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Advisor Group Holdings, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Advisor Group Holdings, Inc. with notifications on news.